Results 171 to 180 of about 67,479 (216)

Using the Scaffold of FDA-Approved Drugs with Trypanocidal Activity to Identify New Anti-<i>Trypanosoma cruzi</i> Agents: An In Silico and In Vitro Approach. [PDF]

open access: yesMolecules
Vázquez-Jiménez LK   +9 more
europepmc   +1 more source

Protein Kinase Inhibitors and Oxidative Stress Modulate In Vivo Phosphorylation of <i>Trypanosoma cruzi</i> DNA Polymerase β. [PDF]

open access: yesPharmaceutics
Maldonado E   +9 more
europepmc   +1 more source

New Histone H4 variant and H2B variant Exhibits distinct genomic distributions, chromatin affinities, and dynamics throughout life and cell cycle of Trypanosoma cruzi. [PDF]

open access: yesPLoS Pathog
Roson JN   +10 more
europepmc   +1 more source

Effect of mixed infection with Trypanosoma cruzi and the fungus Metarhizium anisopliae on survival, parasitemia, and immune response in Triatoma pallidipennis (Hemiptera: Reduviidae). [PDF]

open access: yesJ Med Entomol
Flores-Villegas AL   +9 more
europepmc   +1 more source

Differentiation of "Trypanosoma cruzi", "T. cruzi marinkellei", "T. dionisii" and "T. vespertilionis" by monoclonal antibodies

Acta tropica, 1986
Anti-T. dionisii and anti-T. vespertilionis monoclonal antibodies secreted by 17 hybridoma clones were tested against various strains of T. dionisii, T. vespertilionis, T. cruzi and T. cruzi marinkellei. Strain and species specific antigens were detected for the homologous immunizing strains.
K, Petry, T, Baltz, J, Schottelius
openaire   +2 more sources

Triatominae–Trypanosoma cruzi/T. rangeli: Vector–parasite interactions

Acta Tropica, 2009
Of the currently known 140 species in the family Reduviidae, subfamily Triatominae, those which are most important as vectors of the aetiologic agent of Chagas disease, Trypanosoma cruzi, belong to the tribes Triatomini and Rhodniini. The latter not only transmit T.
G A, Vallejo, F, Guhl, G A, Schaub
openaire   +2 more sources

Role of ROS in T. cruzi Intracellular Development

2019
Chagas disease, caused by the protozoan Trypanosoma cruzi, presents a variable clinical course ranging from asymptomatic cases to more severe forms with cardiac, digestive, or cardio-digestive impairment. The factors involved in this clinical heterogeneity are not completely understood, but certainly both host and parasite genetic variability are ...
Luciana O. Andrade   +1 more
openaire   +1 more source

Home - About - Disclaimer - Privacy